The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Jean-Jacques Kiladjian
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Approximately how many patients with myelofibrosis have anemia at the time of diagnosis?
A
B
C
D
During an MPN Hub symposium presented at the European School of Haematology (ESH) 4th How to Diagnose and Treat CML/MPN conference, MPN Hub steering committee Chair Jean-Jacques Kiladjian, Université Paris Cité and Hôpital Saint-Louis, Paris, FR, presented a review of anemia in myelofibrosis (MF), with a focus on the impact of anemia on patient outcomes.
Anemia in myelofibrosis: Impact on patient outcomes
Key points
- MF is associated with a range of clinical manifestations and constitutional symptoms, including anemia, that significantly impact patient outcomes.
- The cause of anemia in MF is multifactorial, including splenomegaly-induced hemodilution and increases in plasma volume, red blood cell sequestration and destruction, and ineffective erythropoiesis; it can also be caused or exacerbated by certain MF treatments.
- Anemia is prevalent in patients with MF, with ~40% of patients anemic at diagnosis and ~25% of patients transfusion dependent at diagnosis, rising to almost 60% and 50% respectively within the first year of diagnosis and increasing further over time. It is often severe (defined as <8g/dL hemoglobin or transfusion dependence).
- Anemia is included in all MF prognostic scoring systems, and both anemia severity and transfusion dependence are strongly predictive of reduced QoL and survival outcomes in patients with anemia.
- Anemia and increasing severity of anemia significantly reduce OS for patients with MF.
- The median OS in transfusion-independent patients is ~62 months, and only ~22 months in highly transfusion-dependent patients.
- Transfusion burden can impact employment and social life.
- Improving anemia is an important goal alongside targeting spleen size and symptoms for improving everyday QoL and long-term outcomes in patients with MF.
- Anemia therefore represents an important consideration for treatment decision-making.
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
